How Wider Q1 Losses and FDA Priority Review for Zanidatamab At Zymeworks (ZYME) Has Changed Its Investment Story
Simply Wall St
Last updated: May 11, 2026
Zymeworks Inc. released its first-quarter 2026 financial results, revealing a significant increase in its net loss to US$44.16 million, largely attributed to reduced milestone revenue. The company also reported a basic loss per share of US$0.59 for the period.
- Zymeworks' first-quarter 2026 performance was impacted by a decrease in milestone revenue, contributing to a wider net loss. The company's financial report indicated a net loss of US$44.16 million and a basic loss per share of US$0.59. These figures reflect the financial outcomes for the initial quarter of 2026. No further details regarding specific operational achievements or challenges were provided in the excerpt beyond the financial reporting. The report did not include any forward-looking statements or indications of future performance expectations. The disclosed financial results are based solely on the reported quarter.
